1.68 mL of Alloc-Cl is dissolved in 5 ml of dioxane and 1.54g of sodium azide dissolved in 4 mL of water is added and stirred for 2 hours. Then, 2.5g of N-Ile-OH are dissolved in 50 mL water containing 4g of sodium carbonate is added to the mixture followed by 50mL dioxane. The reaction mixture stirred at rt 24 hours monitoring the pH which should be between 8 and 10. The pH is adjusted by adding sodium carbonate 10%.
Experimental section
Synthesis of Alloc amino acids 1.68 mL of Alloc-Cl is dissolved in 5 ml of dioxane and 1.54g of sodium azide dissolved in 4 mL of water is added and stirred for 2 hours. Then, 2.5g of N-Ile-OH are dissolved in 50 mL water containing 4g of sodium carbonate is added to the mixture followed by 50mL dioxane. The reaction mixture stirred at rt 24 hours monitoring the pH which should be between 8 and 10. The pH is adjusted by adding sodium carbonate 10%.
Once the reaction is finished, the solvent mixtureis evaporated using vacuum evaporator then wash the crude several times using hexane. 100mL of water is added keeping the pH adjusted to between 9 and 10 and washed (3v X 50mL) with diethylether.
The aqueous phase is acidified with HCl to pH 2 and extracted with DCM, dried with anhydro magnesium sulfate, DCM was evaporated and characterized HPLC, HPL-MS, NMR and they matched the spectra in literature.
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Synthesis of modifiedanalogues of L-Arg teixobactin a) Synthesis of tetrapeptide (in all cases except Lys 11 -Teixobactin)
166 mg of 2-Cl-Trt resin (1.69 mmolg -1 ) was placed in a 10mL falcon tube and then was activated by 10 % SOCl 2 in DCM for overnight. The resin was transferred into 10 mL polypropylene syringe fitted with a polyethylene filter disc and washed several times with DCM. Then, it washed with DCM (3 × 10 mL, 1 min) followed by adding the first amino acid Fmoc-L-A.A.-OH (0.1 mmol) and DIEA (174 µL, 1 mmol, 10 equiv) in 0.5mL DCM and shacked for 1 h. Then 100 µL MeOHwas added and shacked for 30 min to ensure full capping of the resin. Then the resin was washed with DMF (2 × 10 mL, 1 min), DCM (2 × 10 mL, 1 min), Methanol (2 × 10 mL, 1 min), DCM (2 × 10 mL, 1 min) and S2 DMF (2 × 10 mL, 1 min). Then, Fmoc removal was achieved by 20% piperidine in DMF (2 × 10 mL, 5 min). Then, the next amino acids were added by using the following coupling condition:
For coupling:Fmoc-A.A.-OH/HATU/DIEA (3:3:6) in 0.5 mL DMF for 30 min
For Fmocremoval: 20% piperidine in DMF (2 × 10 mL, 5 min).
Washing: DMF (2 × 10 mL, 1 min), DCM (2 × 10 mL, 1 min) and DMF (2 × 10 mL, 1 min).
Until getting tetrapeptide, mini-cleavage was performed in order to monitor the pre-esterification step using analytical HPLC and LC-MS using the same condition as our previous work. 
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The resin was dried under vacuum and transferred onto microwave vial shielded from light by aluminum foil. Then, A solution of phenylsilane (124 µL, 1 mmol, 10 equiv) and a catalytic amount of tetrakistriphenylphosphine palladium (0) (11mg,0.01mmol, 0.1equiv) in dry DCM (1mL) was added. The reaction vessel was flushed with nitrogen and shacked for 15 min. Mini-cleavage was performed in order to control the reaction.
Then, Alloc-L-Arg(Pbf)-OH was added to the resin followed by removal of the Fmoc group and adding the following building blocks on the same order using the same protocol that mentioned above.
Alloc deprotection takes place to give the free L-Arg(Pbf)-OH before cyclization. The resin was dried under vacuum and treated with 1% TFA in DCM (5 × 30s) and collected over water. Then, TFA and DCM were evaporated, and then lyophilization takes place to get the protected powder before cyclization.
d) Cyclization and removing of all protecting groups:
In 1000 mL round flask, DIEA (6 equiv), Oxyma Pure (3 equiv) dissolved in DCM were added to 11-mer depsipeptide(1 equiv) in 0.5 mL DMF. Then, it cooled to 0 °C by ice bath followed by adding PyAOP (3 equiv) to the reaction mixture. The reaction was stirred 24h. (The peptide concentration must not be more than 0.0001M).
Then, DCM was removed by rotary evaporator while DMF was removed using phase drying. 5 mL of the TFA/TIS/H 2 O (95:2.5:2.5) was added and stirred for 4 h. The solvent and residues from the cleavage cocktail were concentrated under nitrogen. The crude peptide was precipitated and washed with cold Et 2 O (3 × 10 mL). The crude peptide was confirmed by HPLC and MALDI-TOF.The crude peptide was purified by prep-HPLC using the following condition:A linear gradient of 30-50% CH 3 CN/H 2 O and 0.1% TFA over 30 min was applied, with a flow rate of 7.0 mL/min and detection at 220 nm using a PhenomenexLunaC18(2) 100A• column (10 µm × 250 mm). 
Minimum Inhibitory Concentration (MIC) determination 3
The MIC was determined using the broth microdilution method as described by the Clinical and Laboratory Standards Institute (CLSI) guidelines. Briefly, two-fold serial dilutions of each drug/compound were done in cation adjusted Mueller Hinton broth (CAMHB) in a 96 well microtitre plate. The bacterial inoculum was prepared in distilled water and matched to a 0.5 McFarland standard and added to make a final volume of 200µl in each microtitre well. The plates were incubated for 24 hours at 37 o C under aerobic conditions. The MIC was then recorded, as the lowest concentration at which there was no visible growth. A drug free and media control wells containing bacteria and CAMHB respectively were included in each plate. Meropenem was also tested as drug control. The assay was done in duplicate to confirm results
